Sign In

Use the Qualified Clinical Data Registry (QCDR) to complete Merit-Based Incentive Payment System reporting.

Report on evidence-based quality measures and receive performance scores via the Quality Oncology Practice Initiative (QOPI®).

Oncology Practice Insider

ASCO’s Oncology Practice Insider provides the latest news, information, and educational tools to assist with the successful management of oncology practice and the delivery of high quality patient care. OPI offers updates on ASCO programs, services, and cancer-related health policy, Medicare news, and billing and coding best practices. To sign up for the biweekly Oncology Practice Insider newsletter, please complete this form.

On November 16, ASCO published the Systemic Therapy for Advanced Hepatocellular Carcinoma Guideline. Atezolizumab bevacizumab (atezo bev) may be offered as first-line treatment of most patients with advanced HCC, Child-Pugh class A liver disease, Eastern Cooperative Oncology Group Perfor-mance Status (ECOG PS) 0-1, and following management of esophageal varices, when present, according to institutional guidelines.
Oncology providers familiar with the American Society of Clinical Oncology’s (ASCO) guideline on older adults with cancer are two to four times more likely to conduct a geriatric assessment on patients with cancer over the age of 65, according to the first international ASCO survey aimed at determining if and how often cancer providers are using geriatric assessments when treating older adults.
Here are two guidelines updates recently published:
On June 22, 2020, ASCO posted the Treatment of Locally Advanced Esophageal Carcinoma: ASCO Guideline. Multimodality therapy for patients with locally advanced esophageal carcinoma is recommended.
On April 23, ASCO posted the Diagnosis and Management of Squamous Cell Carcinoma of Unknown Primary in the Head and Neck guideline.
ASCO Clinical Practice Guidelines Committee (CPGC) is soliciting topics for clinical practice guideline development, and the CPGC would like to invite members of other ASCO Committees to participate in the process. The CPGC has delegated the identification and prioritization of guideline topics to Guideline Advisory Groups (AGs). The AGs will consider topics suggested by the ASCO membership when revisiting current priorities and will submit the prioritized list to the CPGC in the fall.
On March 31, ASCO posted the Systemic Therapy for Melanoma Guideline. Immunotherapy is recommended as the standard for BRAF wild-type, unresectable/metastatic melanoma, while either immunotherapy or BRAF/MEK targeted therapy is recommended for BRAF mutant disease.
On March 9, 2020, ASCO published the Treatment of Patients with Late-Stage Colorectal Cancer Resource-Stratified Guideline. The expert panel provided recommendations for diagnosis, systemic treatment, and surgery.